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Background: Reports on percutaneous cryoablation to treat patients with HCC are sparse in the medical
literature. This study aimed to determine the safety and efﬁcacy of percutaneous cryotherapy for
unresectable or recurrent hepatocellular carcinoma (HCC).
Methods: The results of 40 patients with unresectable HCC and 26 patients with recurrent HCC treated
with ultrasound-guided percutaneous cryotherapy from January 2006 to June 2009 were retrospectively
analyzed.
Results: We used percutaneous cryotherapy to treat 76 tumors in 40 patients with unresectable and 76
tumors in 26 patients with recurrent HCC. The size of the tumors was 2.8  1.7 cm (mean  S.D.). The
mean number of treatment sessions for unresectable and recurrent HCC were 1.7 and 1.4, respectively. All
cryotherapy procedures were technically successful. No procedure-related death was observed. The
overall complication rate was 12.1%. Patients with unresectable HCC had 1-, and 3-year overall survival
rates of 81.4%, and 60.3%, while the disease-free survival rates at 1 year and 3 years were 67.6% and 20.8%,
respectively. Patients with recurrent HCC had 1-, and 3-year overall survival rates of 70.2%, and 28.8%,
while the disease-free survival rates at 1 year and 3 years were 53.8% and 7.7%, respectively.
Conclusion: Ultrasound-guided percutaneous cryotherapy was safe and efﬁcacious in the treatment of
unresectable and recurrent HCC. Further randomized trials are needed to compare the safety and efﬁcacy
of cryotherapy with other forms of percutaneous treatment so that an unbiased therapeutic strategy can
be devised.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is a major health problem
worldwide, with an estimated incidence of new cases ranging
between 500,000 and 1,000,000 annually. It is the ﬁfth most
common cancer in the world, and the third most common cause of
cancer-related death.1,2 For years, partial hepatectomy and liver
transplantation have been considered as the main curative treat-
ments. Various locoregional therapies have been used for patients
who are not candidates for surgical cure. Local ablative therapy has
been commonly used in patients with small HCC conﬁned to the
liver, especially when the tumors are unresectable due to poor
general condition or because of compromised liver function.3e6 The
goal of treatment for these patients is to prolong life. TheChinese University of Hong
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ciates Ltd. Published by Elsevier Ltapplication of local ablative therapy has a number of potential
advantages in patients with high surgical risks. The procedure is
relatively safe and well tolerated and its complication rates in most
series have been low. Currently, the most widely favored technique
is radiofrequency ablation (RFA) but developments in other tech-
niques may change this. Cryotherapy offers an alternative treat-
ment for patients with unresectable HCC. While cryoblation has
been shown to induce growth inhibition of unresectable tumors7
and tumor metastases8e10 as a consequence of stimulation of
cryo-immunity11 and production of pro-inﬂammatory
cytokines8e11 and natural killer cell function,12 no such effects can
be shown after thermal ablation.1314 The margins of cryoablated
lesions are very clearly demarcated from normal tissue on ultra-
sound (USG). The ability to monitor the ablation process precisely
with an accuracy of 1e5 mm by USG is an advantage of cryotherapy
over the other currently available local ablative therapies. In the
past, the development of cryotherapy was hampered by its need for
laparotomy and the comparatively higher incidence of complica-
tions. With technological reﬁnements with smaller cryoprobes and
the experience gained in USG, percutaneous cryotherapy has been




HCC n ¼ 40
Recurrent
HCC n ¼ 26
Age (years) 59.3  10.6 57.4  13.9
Gender (Male/Female) 33/7 22/4
Hepatitis status
Hepatitis B carrier 38 25
Hepatitis C carrier 2 1
Cirrhotic liver 34 22
Liver function status at time of partial hepatectomy
Child-Pugh class A 12 6
Child-Pugh class B 24 18
Child-Pugh class C 4 2
AFP level (ng/ml) [median (range)] 410.0 (2.6e3690.8) 69.7 (2.1e466)
Preoperative laboratory results [median (range)]
Hemoglobin (g/dL) 12.46(9.5e14.3) 13.01(10.4e15.4)
Platelet count (109/L) 171.0 (69e357) 146.5 (63e208)
International normalized ratio (INR) 1.05 (0.9e1.48) 1.05 (0.85e1.54)
Bilirubin (umol/L) 16.4 (8.6e32.1) 17.4 (8.1e37.5)
Albumin (g/L) 39.3 (28.4e50.1) 17.4 (8.1e37.5)




HCC n ¼ 40
Recurrent
HCC n ¼ 26
Complications
Post-operative hemorrhage 0 1
Cryoshock syndrome 0 0
Bile leak 0 1
Intra-abdominal collection 1 2
Acute tubular necrosis 1 0
Liver failure 0 0
Wound infection 1 1
Hospital mortality 0 0
Mean hospital stay (days) 3.4  1.5 4.0  1.8
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sectable HCC.
This study aimed at determining the safety and efﬁcacy of
percutaneous cryotherapy for unresectable or recurrent HCC.
2. Methods
2.1. Study
Between January 2006 to June 2009, 40 patients with unresectable HCC and 26
patients with recurrent HCC after ‘curative’ partial hepatectomy underwent percu-
taneous cryotherapy of HCC at the Department of Hepatobiliary Surgery, The First
People’s Hospital of Foshan, China. Patients selected for percutaneous cryotherapy
had no evidence of extrahepatic disease but were not candidates for curative
surgical resection due to the location or size of HCC and/or the presence of severe
hepatic dysfunction/medical comorbidities. Inclusion criteria for the study were: (a)
adult patient with either a single HCC smaller than or equal to 7 cm in diameter or
multiple (up to three) HCCs smaller than or equal to 3 cm in diameter each, (b).
Written informed consent was obtained from all patients.
2.2. Treatment procedure
The patient was placed in a supine or a left lateral position. Cryotherapy was
performed by a percutaneous approach using real-time USG guidance under intra-
venous sedation and local anesthesia. Dedicated 3.5-MHz probes for US-guided
interventions were used. Procedures were performed by experienced interventional
radiologists. The cryoablation system (CRYO-HIT System; Galil Medical Ltd,
Yokneam, Israel) that we used enabled independent and simultaneous operation of
as many as 25 cryoprobes. The cryoprobe was a sealed 1.47-mm-diameter (17-
gauge) needle that could generate an ice ball of 3 cm in diameter and 5 cm in length
along the probe shaft. Cryoprobe positions were determined according to tumor
geometry and expected ice ball size. The rapid expansion of argon gas in a sealed
cryoprobe with a distal uninsulated portion resulted in rapid freezing of tissue, and
temperatures reached below70 Cwithin seconds. The diameter of the ice ball was
controlled by the rate of gas delivery to the probe. Thawing was achieved by
replacing the argon gas with helium gas. Each lesion received a single treatment of 2
cycles of freezing (10 min), thawing (5 min), refreezing (10 min), and thawing
(5 min). Tumor freezing was monitored by USG until the ice ball enveloped the
tumor with a 1-cm margin of normal tissue. For larger tumors, multiple cryoprobes
were positioned at 1 cm apart and treatment success was deﬁned as extension of the
ice ball 1 cm beyond all the tumor margins.
2.3. Post-treatment assessment and follow-up
After cryotherapy, the patients underwent close observation. Complete blood
picture, renal function tests and liver function tests were assessed immediately
postoperatively and in the next morning. All patients stayed in the hospital over-
night. Any adverse event was evaluated and recorded.
A routine intravenous contrast enhanced spiral computed tomography (CT) scan
or magnetic resonance imaging, (MRI) was performed 1 month after crytotherapy.
The follow-up protocol included alpha-fetoprotein (AFP) level and USG at 3-monthly
intervals, and intravenous contrast enhanced spiral CT/MRI, at 6-monthly intervals.
Patients were observed for recurrence of the treated tumor and for new HCC.
Tumors that exhibited local tumor progression and new HCC tumors during follow-
up were treated with cryotherapy if the patient still met the inclusion requirements.
2.4. Statistical analysis
Preoperative and postoperative data were entered into a prospective database.
The data was analyzed retrospectively.
Treatment success was deﬁned as extension of the ice ball 1 cm beyond the
tumor margin and absence of contrast enhancement during the 1 month post-
procedural contrast CT scan/MRI.
Survival probabilities were estimated by the KaplaneMeier method. Survival
outcome was compared by log-rank test. Overall survival was deﬁned as the time
from the treatment to the last follow-up or death. Recurrence interval was deﬁned as
the time from the treatment to the ﬁrst follow-up imaging investigation that
revealed either local tumor progression or new HCC. P-value < 0.05 was considered
as statistically signiﬁcant.
3. Results
During the study period, we used percutaneous cryotherapy to
treat 76 tumors in 40 patients with unresectable HCC and 76
tumors in 26 patients with recurrent HCC. These 66 patients
included 55 men and 11 women, and their mean age  S.D. was58.6 12.0 years. Patients’ characteristics are shown in Table 1. The
reasons of unresectability included: - 1) limited hepatic reserve
(n ¼ 23); 2) multiple, bilobar disease (n ¼ 10); 3) general condition
too poor for partial hepatectomy (n ¼ 7). The mean size  S.D. of
the tumors was 2.8  1.7 cm (range, 0.8e7.0 cm). The follow-up
period ranged from 4 to 40 months (median, 26 months).
3.1. Procedure related mortality and morbidity
All cryotherapy procedures were technically successful. The
mean hospital stay was 3.6  1.6 days. No procedure-related death
was observed. Complications occurred in 8 patients (12.1%)
following cryotherapy. (Table 2)
3.2. Treatment success
3.2.1. Unresectable HCC
The initial success following 1 treatment was 62.5%. In those in
whom initial success was not achieved, retreatment was under-
taken in 15 (37.5%) of 40 patients (2 sessions, n ¼ 7; 3 sessions,
n ¼ 6; 4 sessions, n ¼ 1; 5 sessions, n ¼ 1). The overall success
following 1 or more treatments was 75%. The mean treatment
session was 1.7.
3.2.2. Recurrent HCC
The initial success following 1 treatment was 69.2%. In those in
whom initial success was not achieved, retreatment was under-
taken in 8 (30.8%) of 26 patients (2 sessions, n ¼ 6; 3 sessions,
n ¼ 2). The overall success following 1 or more treatments was
76.9%. The mean treatment session was 1.4.
Fig. 2. Overall survival curve of patients with recurrent HCC (n ¼ 26).
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3.3.1. Unresectable HCC
Serum AFP levels were increased in 24 of 40 patients at the time
of diagnosis. After cryosurgery, a drop was observed in 23 patients
(95.8%). Among these 23 patients, a drop to normal level was
observed in 17 patients. An increase in serum AFP level was
observed in 1 patient (4.2%). Preoperative AFP levels fell from
a mean of 410.0 mg/mL to 11.1 mg/mL.
3.3.2. Recurrent HCC
Serum AFP levels were increased in 13 of 26 patients at the time
of diagnosis. After cryosurgery, a drop was observed in 12 patients
(92.3%). Among these 12 patients, a drop to normal level was
observed in 8 patients. An increase in serum AFP level was
observed in 1 patient (7.6%). Preoperative AFP levels fell from
a mean of 69.7 mg/mL to 12.6 mg/mL.
3.4. Tumor recurrence and survival
3.4.1. Unresectable HCC
Patients with unresectable HCC had 1-, and 3-year overall
survival rates of 81.4%, and 60.3%, respectively. (Fig. 1)
During follow-up, recurrence of the treated tumor (i.e., local
tumor progression) was observed in 14 tumors in 12 patients. The
1-, and 3-year local tumor progression rates were 25%, and 30%,
respectively. New HCC appeared in 8 of 40 patients. The recurrence
rates of new tumors at 1 and 3 years were 12.5% and 20%, respec-
tively. The overall recurrence rates were 32.5% at 1 year, and 42.5%
at 3 years.
Subgroup analysis was performed for the different reasons of
unresectibility of HCC before the cryosurgery - 1) limited hepatic
reserve (n ¼ 23); 2) multiple, bilobar disease (n ¼ 10); and 3)
general condition too poor for partial hepatectomy (n ¼ 7). During
follow-up, the overall recurrence rates were 10 in 23 patients
(43.5%), 4 in 10 patients (40%) and 3 in 7 patients(42.9%), respec-
tively. The 1-year/3-year overall survival rates were 86.2%/52.4%,
76.1%/59.8% and 81.9%/68.7%, respectively.
3.4.2. Recurrent HCC
Patients with recurrent HCC had 1-, and 3-year overall survival
rates of 70.2%, and 28.8%, respectively. (Fig. 2)
During follow-up, recurrence of the treated tumor (i.e., local
tumor progression) was observed in 8 tumors in 6 patients. TheFig. 1. Overall survival curve of patients with unresectable HCC (n ¼ 40).1-, and 3-year local tumor progression rates were 15.4%, and 23.1%,
respectively. New HCC appeared in 23 of 26 patients. The recur-
rence rates of new tumors at 1 and 3 years were 73.1% and 88.5%,
respectively. The overall recurrence rates were 76.9% at 1 year, and
92.3% at 3 years.
Subgroup analysis was performed for the different reasons of
unresectibility of HCC before the cryosurgery - 1) limited hepatic
reserve (n¼ 5); 2) multiple, bilobar disease (n¼ 18); and 3) general
condition too poor for partial hepatectomy (n ¼ 3). During follow-
up, the overall recurrence rates were 4 in 5 patients (80%), 17 in
18 patients (94.4%) and 3 in 3 patients(100%), respectively. The
1-year/3-year overall survival rates were 80%/20%, 61.1%/33.1% and
66.7%/33.3%, respectively.
3.4.3. Prgonostic factors analysis
Prognostic factors of size and number of tumors were analyzed
for all patients (n ¼ 66). There was no signiﬁcant difference in
overall survival (median survival, 29.0 months vs. 30.0 months,
p ¼ 0.807) in those patients with tumor sized </ ¼ 2 cm (n ¼ 13)
and > 2 cm (n ¼ 53). There was no signiﬁcant difference in overall
survival (median survival, 32.0 months vs. 20.0 months, p ¼ 0.379)
in those patients with a single tumor focus (n ¼ 44) and 2 or more
tumor foci (n ¼ 22).
4. Discussion
The principle of cryotherapy involves the destruction of tissue
using extreme cold temperatures via the formation of intracellular
crystals. A rapid freeze-thaw process is used to initiate cellular
membrane disruption and cell death. Cryotherapy of a 1-cmmargin
of normal tissue beyond the tumor margin is recommended for
achieving adequate tumor ablation with 2 cycles of cryotherapy.15
Open approaches increase the chance of detection of unknown
intrahepatic and extrahepatic tumors because they allow complete
abdominal exploration and intraoperative ultrasound assessment.
The additional advantages of the open approach is the accurate
placement of electrodes and the possible treatment of tumors in
percutaneously inaccessible areas of the liver and tumors in close
proximity to or invading the adjacent organs. As one moves from
open to percutaneous techniques one loses the advantages of the
open approach but gains the advantages of the minimal invasive
approach.16
RFA constitutes the most extensively studied local ablative
therapy. Findings from recent studies have shown that in small
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treatment sessions than other local ablative techniques, such as
percutaneous ethanol injection or microwave coagulative
therapy.17 Currently, RFA is the most widely used local ablative
technique. However, the safety of percutaneous cryotherapy when
compared with RFA is still unclear, as most RFA series have been
done percutaneously, and most cryotherapy has been done with
open surgery. Percutaneous cryotherapy has theoretical advantages
over percutaneous RFA in the treatment of HCC. First, cryoablation
has been shown to induce growth inhibition of unresectable
tumor7 and tumor metastases.8e10 The mechanism is through the
stimulation of cryo-immunity,11 production of pro-inﬂammatory
cytokines through activation of Kupffer cells and then macro-
phages,8e10 and activation of killer cell function.12 On the other
hand, thermal ablation can accelerate growth of any residual tumor
by local inﬂammatory changes induced by the heat-coagulation
action. Such a heat induced tissue damage is found to produce
several growth factors such as ﬁbroblast growth factor and tumor
growth factor which may actually enhance tumor growth.13,14
Second, and most important, real-time USG accurately monitors
the cryoablation procedures and supplies three dimensional views
of the ice ball as it develops. Third, it produces ice balls of
a consistent size and shape, and it reliably causes cell death within
the cryolesion. Fourth, multiple probes can be used concurrently,
which is important for limiting the time of treating larger lesions.
Fifth, direct monitoring of the cryoablation process and the good
control of the cryoablation system by regulating any speciﬁc
cryoprobe to slow or to stop at will the freezing process if the
growing ice ball is approaching a vital structure. The previous
disadvantages of cryotherapy have now been overcome with the
new design of the probe with a much smaller diameter size. The
large diameter of the old probes (minimum 3.5 mm for a liquid
nitrogen system) essentially precluded percutaneous use, and
might caused cracking of cryolesions which accounted for a signif-
icant proportion of cryotherapy-associatedmorbidity in the form of
bleeding.
The majority of data published on percutaneous cryotherapy
have been on patients with colorectal metastases.1821 The data on
cryotherapy on HCC is lacking, with only a series of patients with
HCC treated with open-laparotomy cryotherapy,22 and a small
series with initial results using percutaneous cryotherapy.23 Our
cohort study showed USG-guided percutaneous cryotherapy for
unresectable HCC or recurrent HCC was safe and efﬁcacious. The
mid-term survival result was favorable. The mortality rate was 0%
and the complication rate was low. Cryoshock, presenting with
multiorgan failure, severe coagulopathy, disseminated intravas-
cular coagulation, and a high mortality rate, which was associated
with approximately 1% of hepatic cryoablations with the use of the
old cryoprobe, has not been seenwith our treatment using the new
percutaneous cryoprobes.
In conclusion, percutaneous cryotherapy was safe and efﬁca-
cious for the treatment of unresectable or recurrent HCC. Further
randomized trials are needed to establish the clinical efﬁcacy of
cryotherapy in comparison with other percutaneous treatments so
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